Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Piers Ingram, founder and CEO of Singapore-based Hummingbird Bioscience and its U.S. spin-off Callio Therapeutics, is quietly ...

The Allan Labor Government is backing a new, world-class facility in Victoria - the first in Australia accredited to manufacture a groundbreaking new ...

WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE ...

A groundbreaking NHS therapy for myeloma uses a 'Trojan horse' approach to target cancer cells, offering longer remission, ...

The shares of this leading pharmaceutical company are in focus after the company secured the USFDA's approval for its key ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Bernard Mahon was initially refused access to treatment with pembrolizumab by his private health insurer, Laya Healthcare, before running a social media campaign to raise awareness about it ...

Preclinical studies suggest ivermectin may be effective against some cancer cell lines in high doses, Johnson said. In a 2021 ...

Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...

Cancer is costly for patients and the NHS—but it also has a significant impact on the U.K. economy, according to research led ...